INTRODUCTION
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is one of the most common devastating and fatal neurodegenerative disorders, characterized by the progressive and relatively loss of motoneurons, paralysis, atrophy of muscle tissues and death. There is no treatment that could relieve the disease burden because of incomplete understanding of ALS etiology (1). Currently, there is only one FDAapproved compound; riluzole does not resolve the disease, but slows progression and extends survival with modest effects (2, 3). The genetic causes of ALS is still under investigation; approximately 10% of ALS cases are inherited (familiar ALS), associated to dominant mutations in or deletion of the cytosolic Cu/ Zn superoxide dismutase 1 gene (4), but 90% of them are sporadic or originated from unknown genetic factors (5,6). Other genes implicated in ALS are TAR DNAbinding protein (7-9), fused in sarcoma protein (10, 11), ALS2/alsin (12), ALS4/senataxin (13), or ALS8/vesicleassociated membrane protein-associated protein B (14), neurofilament heavy peptide (15), angiogenin (16), ubiquilin 2 (17), optineurin (18) and C9ORF72 (19, 20) . Several molecular mechanisms have been proposed to elucidate the pathophysiological pathways contributing to motor neuron degeneration in ALS, including oxidative stress, glutamate excitotoxicity, mitochondrial dysfunction, dysregulation of RNA processing, protein aggregation, disordered axonal transport and inflammation, abnormal neurofilament function (21-27). Gene expression microarray technology is characterized as a powerful high throughput tool capable of monitoring the expression of thousands of genes in an organism simultaneously (Figure 1 ). In biomedical research, DNA microarrays initially were designed to measure the transcriptional levels of RNA transcripts derived from thousands of genes in different cell types and tissues (28, 29) . More recent implications of DNA microarrays are useful in SNPs detection, RNA splicing and biomarkers determination (30, 31) . A significant number of microarray studies has been tried to identify reactive oxygen species, such as superoxide anion, hydroxyl radical, hydrogen peroxide and peroxynitrite. Upon mitochondrial stress in the majority of ALS models, SOD1 may undergo oxidative activation, competing with cytochrome C for superoxide released in the mitochondrial intermembrane space, leading to increased ROS production among with increased lipid peroxidation and DNA/RNA oxidative modifications (46-48). The mechanism mutant SOD1 causing direct and glia-mediated neurotoxicity is not fully understood, with NADPH oxidase activation and superoxide production are belonged to the most studies contributors to motoneuron death (49-51). Previous studies have demonstrated the link between oxidative stress and cell death in ALS, such as the factional role of transcriptional factor 53 in motor neuron death in mice (52) or alterations in genes involved in regeneration and tissue degradation (53). Using Mouse Genome 430 2.0. Array from Affymetrix, different mechanisms of neuronal death under oxidative stress or excitotoxic stress were analyzed in two independent cultures of primary cortical neurons of SOD1G93A animals or nontransgenic in response to the cellular stress induced by the NMDA or hydrogen peroxide (54). In SOD1G93A cortical neurons, proteasome-targeting factors such as ubiquitin associated protein 2-like, ubiquitin-conjugating enzyme E2W or ubiquitin-conjugating enzyme E2I subjected to NMDA and autophagosomal protein or proteasome subunit (PSMA6) subjected to NMDA and cytokine transcripts were found upregulated related to nontransgenic one. Utilizing SOD1G93A neurons subjected to hydrogen peroxide, microarray analysis identified altered transcriptional profiling in genes related to controlling actin-associated cytoskeletal remodeling and exogenesis, wnt signaling pathway regulators, trophic factors or ion transport (ARAP2, KIF17, Dickkopf homolog 2, IGFBP4, FGF17, PTGER3, KCNA5, and TRPV1). In another study by Zhang group, Affymetrix GeneChip Drosophila Genome 2.0. arrays were applied to investigate the cell-specific expression of mutant SOD1 in neuronal cells of flies utilizing young and old flies (5 days and 25 days respectively) with SOD1 G85R (G85R) expression in motoneurons and glia (55). Depending on the age of flies and cell specific expression of G85R; motoneuron, glia or both, an altered expression of G85R was observed, affecting pathways related to oxidative stress, lipid metabolism, signaling genes and development of nervous system. Focusing on oxidative stress, numerous genes related to pentose-phosphate pathway, glutathione transferase activity and NADP metabolism were found downregulated, especially in models expressing G85R in motoneurons. Older flies expressing G85R were characterized by increased stimulation to hydrogen peroxidation in motoneuron and glia demonstrating oxidative stress as a potent contributor to the pathology of ALS (55).
In the outstanding work by the Shaw group, Health et al. attempted to summarize in depth the applications of the transcriptomic technology in order to examine changes associated among ALS tissues. Gene expression was examined at the level of the tissue and individual cell types in both sporadic and familial forms of the disorder elucidating the mechanisms associated to motor neurons death (56). In a second work by the same group, in order to identify pathways in disease pathogenesis and potential therapeutic targets, microarray human gene expression profiling studies in mixed-cell samples, laser capture microdissection cell samples and peripheral tissue have been summarized, unraveling characteristic key-molecules related to neuroinflammation, RNA splicing and cytoskeleton involvement (57). The importance of microarraybased transcriptomics analysis was also evaluated to identify strategies related to pharmacological targeting interpreting altered pathways and networks (58), while the major findings of numerous studies that have been analyzed using global gene expression in tissues and cells from biopsy or post-mortem specimens of ALS patients or specific animal models (59). These studies corroborated the implication of previously described The significant role of cytoskeleton-related genes in motor neurons and Schwann cells in the presymptomatic stages of ALS disease was identified for the first time using Agilent Whole Mouse Genome Oligo 4×44 K (60). Differentially expressed genes were identified in the spinal cord from 40 and 80 days old SOD1 G93A mice respectively comparing with altered genes in the sciatic nerve from 60 days old mice. GO enrichment analysis was performed and the cellular component GO terms related to microtubule cytoskeleton, actin cytoskeleton and microfilament cytoskeleton were over-represented. G93A mice, which display up-regulation of MHC class I genes, demonstrating the importance of the study in novel therapeutic intervention (65). Postmortem human material additionally to SOD1 G93A ALS and P20L Tau frontotemporal dementia mouse models were exploited to indicate common molecular mechanisms associated to motor neuron degeneration, using Agilent whole mouse genome microarrays (66). The association of altered genes to crucial motor neuron biological processes has been revealed especially on muscle contraction, immune system, stress response, signaling and protein/protein modification regulation. The alterations in gene expression among oculomotor and spinal cord motor neurons in postmortem neurologically human midbrain and spinal cord biopsies were ascertaining using GeneChip Human Genome U133 Plus 2.0. Array from Affymetrix (23). A significant number of deregulated genes related to mitochondrial oxidative phosphorylation, immune system functions, transcriptional regulation, and ubiquitin-mediated protein degradation have been revealed with emphasis on GABAergic and glutamate receptor subunits mediated transmission, indication which rationalizes the strong connection between ALS progression and oculomotor neurons (23). Bernandini et al., using Gene Chip Human Genome Focus Array (Affymetrix), tried to maintain a system based on muscle expression profiles in ALS disease (68). Genes linking with human skeletal muscle structure and metabolic pathways have been observed significantly down-regulated like myosin, myogenin, collagen, Eno3, Fbp2) or up-regulated (forkhead box O, myogenic factor 4, cAMP-dependent protein kinase regulatory subunit RI1 alpha) respectively, additionally to mitochondrial genes like Actn3 and Chrna1 which consist members of oxidative phosphorylation pathway (68). Gene groups associated with cytoskeletal and mitochondrian dysfunction in the motor cortex of patients with sALS have been identified (69). In a further study, microarray data from five dependent muscular tissue diseases, namely ALS, acute quadriplegic myopathy, mitochondrial encephalomyopathy, polymyositis, lactic acidosis and stroke-like episodes and dermatomyositis, have been evaluated trying to provide unique molecular markers for each human muscular disease (70). Analyzing ALS patients data from Affymetrix HG-U133A Platform GPL96 performing a variance modeling approach, myofibril genes like nebulin and alpha F-actin, tropomyosins (Tpm-1/2/3) and troponins (Tnn-c1/c2/ i2/t1) were identified significantly downregulated, while actin-capping proteins like Capza1, Capzb and Tmod1 upregulated respectively. These results indicate the unique role of myofibril gene dysregulation in ALS as a result of actin-myosin interaction inability (70). Whole genome expression profiles of sALS patients motor cortex samples were performed, identifying potent alterations in selectively genes implicated in cell cycle phases, iron regulation homeostasis, cytoskeleton structure development and synaptic plasticity molecular pathways (71). In a recent study, genes implicated in glutamate metabolism, ER stress, activation of chaperones and endoplasmic reticulum response have been indicated differentially expressed among ALS patients with motor neuropathy human motor nerve biopsies (72).
ALS microarrays studies associated with post-transcriptional regulation of gene expression
Alternative splicing of mRNA transcripts with emphasis on the nucleo-cytoplasmic transport, translational silencing and RNA degradation, provides an important mechanism for gene regulation and proteomic diversity generation, diversifying in parallel protein modular functions, with neuronal circuits development and synaptic function and plasticity significant impact (73) (74) (75) . Dysregulations in RNA metabolism, a strong attribute of ALS at multiple levels, contribute to the pathogenesis of the disease, including changes in miRNA biogenesis, spliceosome integrity and RNA editing (76, 77) . Mutations in Tardbp gene have been found in about 3 to 4% of fALS cases and in about 2% of sALS patients (78, 79) . Evidence of the role of mutations in ribosomal proteins TDP-43 and FUS/TLS have been indicated for their contribution in messenger RNA processing and splicing regulation due to their interaction with splicing factors (80, 81) . TDP-43, as a highly conserved heterogeneous nuclear ribonucleoprotein, aggregates in the cytoplasm and nuclear compartments of neurons and glial cells, being often accompanied by nuclear clearance of the protein (82, 83). The availability of genomic technologies provides the convenience to unravel disease mechanisms. Gene expression profiling studies using microarrays have been used in order to investigate the transcriptome profiles of the ribosomal proteins regulation in different ALS-animal models or cell lineages. Applying Affymetrix GeneChip Mouse Gene 1.0. ST arrays on C57BL/6J mouse brain, TDP-43 target genes associated with synaptic function and development were identified, depending on their localization at the presynaptic membrane of axon terminals (84). GO analyses revealed that TDP-43 may be a potent RNA regulator of genes involved in synaptic transmission process such as syntaxins, syntaxin binding proteins, synapsin and synaptophysins (84). An extended microarray analysis on brain of GMR-Gal4/ UAS-TDP-43 transgenic Drosophila model indicated numerous altered genes implicated mainly in cellular oxidative homeostasis and cell cycle regulation. Ucp4b gene profile has been detected upregulated in transgenic flies, while notch genes related to prion disease have been founded upregulated, suggesting that TDP-43 investigates alteration effecting Notch neuronal regulation and intercellular communication pathway in ALS pathogenesis (85). © 1996-2018 of genes with altered expression levels additionally to 10% of genes with differentially spliced exons were similar to the transcriptome profiles of both TDP-43-silenced primary cortical neurons and Fus-silenced primary cortical neurons (90). These results indicate a significant overlap in gene expression alterations sharing also common molecular pathways, suggesting in summary that both TDP-43 and FUS proteins may affect common downstream RNA-regulated cascades which potentially may be associated with the ALS mechanism.
sALS-associated epigenetic marks have been investigated using Illumina Human Methylation 27 DNA BeadChip array, resulting in aberrant gene expression (91). This study examined ALS-dependent methylation dysregulation of several genes previously implicated in neuronal development, differentiation, and proliferation either mutations in genes associated with mental retardation and neurodegeneration, providing a better understanding of disease pathogenesis and facilitate the discovery of new therapeutic targets. In a different study, the transcriptome profile of spinal cord and cerebellum of TIA-1 depleting mice was dissected using GeneChip HT Mouse Genome 430 2.0. Array Plates (Affymetrix), with emphasis in lipid storage and membrane trafficking, demonstrating the role of TIA-1 protein as a potential effector on mRNA lipid homeostasis regulation in the brain (92).
microRNAs IMPLICATION IN AMYOTROPHIC LATERAL SCLEROSIS
Several studies indicate miRNAs as important contributors in motor neuron diseases associated with the central nervous system development, neuronal differentiation and pathogenesis of neurodegeneration (93-95). MiR-34b and miR-9 are playing a potential role in Huntington's disease (96, 97), whereas miR-206, miR-29, miR-132 and miR-153 implicate in Alzheimer's disorder (98-100). In the midbrain of patients with Parkinson's disease, the levels of miR133b have been founded increased, suggesting this agent contribution as a negative regulator of dopaminergic neuron development (101) . Additionally, miR-7 and miR-153 have been identified to regulate alpha-synuclein levels post-transcriptionally (102, 103) . In ALS a number of microarrays studies have identified the essential contribution of microRNAs as significant biomarkers, pathogenesis regulators or potential therapeutic targets as well like mir-9, -23a, -29b, -455, -106, -338-3p and -451 (104) (105) (106) (107) (108) . MiR-155 is presented as a well-promising therapeutic target in ALS supporting pro-inflammatory pathways through interactions with anti-inflammatory molecules like inositol phosphatase SHIP1 and protein kinase phosphatase-1 (109-111). TDP-43 plays an important role in miRNA pathway, while mutations in this protein have been characterized as a common attribute in disease pathogenesis, perturbing miRNAs biogenesis or causing altered expression profiling of mature miRNAs as well (112) . The skeletal muscle-specific miR-206 slows ALS progression by sensing motor neuron injury and promoting the compensatory regeneration of neuromuscular synapses, indicating as a promising candidate molecular marker of this motor neuron disorder (113, 114) .
The miRNAs transcriptome profiling of SOD1 G93A mice brain cortex has been analyzed using mouse miRNA microarrays 8x15K V2 from Agilent Technologies (115) . From a pool of significant hybridized miRNAs of mouse brain microglia the same amount was observed also in the whole immune system and brain whereas in overexpressed transgenic mice a numerous of different miRNAs were founded upregulated. Microarray analysis revealed that miR-155, -146b, -22, -365, -125b, -214 have been identified as key immune system contributors which could control neuroinflammatory pathways, suggesting the strong connection between immune system and brain microglia (115) . The differential profile of miRNAs has been investigated at the spinal cord of SOD1 G93A © 1996-2018 transgenic mouse model using miRCURYTM LNA array v.18.0. from Exiqon, illustrating a huge number of significant deregulated miRNAs (116) . Elevated levels of miRNA-9 three months upon animal death, suggest this molecule as a prominent event in ALS mechanism (116) . In order to determine viable miRNA therapeutic targets for ALS, miRNA transcriptome changes in both SOD1
G93A rat and SOD1 G93A mouse spinal cord tissue have been measured using Affymetrix Mouse Genome 430 2.0. array (109) 
G93A mice upon hybridization on Affymetrix GeneChip miRNA 2.0. chips (113) . Significantly altered miRNAs like miR-1, -133a, -133b, -145, -21, -24 and -206 were identified from extensor digitorum longus muscles and plasma of animals, with muscle-enriched miR-206 being the only one with increased expression among male and female groups at neonatal, pre-or late-symptomatic state of ALS progression. This expression pattern has been evaluated also in human ALS patient's serum, prompting miR-206 as a promising candidate biomarker for this selective motor neuron disease.
The expression profiles of human miRNAs have been analyzed using Miltenyi Biotec PIQO miRXplore microarrays in peripheral leukocytes of sALS partients in an earlier stage of the disease (107) . Numerous microRNAs were revealed down-regulated compared to healthy patients, whereas miR-338-3b was indicated significantly up-regulated in sALS patients' blood, evidence which was found also in brain from ALS patients (117). These specific microRNAs, which were associated for the first time with sALS, play an important role in PI3K/AKT pathway, like miR-451 or miR-638 in nervous system regulation. Raman et al., exploting Applied Biosystems TaqMan Low Density Arrays, determined gene expression transcriptome changes on miRNA levels in human fibroblast cultures, suggesting fibroblasts as a potential disease model for sALS-and PLS-pathophysiological mechanisms study and therapeutic targeting (75) . Comparative analysis identified hundreds of significantly differentially expressed transcripts either in sALS or in PLS fibroblasts respectively, with a variety of genes being implicated in miRNA biogenesis along with transcription, metabolism, RNA processing stress response and signaling (75).
DISCUSSION
ALS is a complex and multifactorial disease characterized by the involvement of several pathogenic conditions. The underlying pathophysiology of ALS is not clearly understood causing by several molecular mechanisms proposed to explain the neuronal degeneration in ALS. Large scale gene expression microarray analyses represent an excellent tool aiming to clarify the disease's molecular pathways complexity either to elucidate the contribution of distinct biochemical pathways of this specific disorder (57). These pathways, as presented in Table 1, encompass  predominantly 
In order to extend microarrays measurements focusing on ALS pathogenetical mechanisms being primarily examined complementary to the transcriptome, the implication of RNA-seq is necessary. Next-generation sequencing technologies are revolutionizing our ability to characterize diseases at the genomic, transcriptomic and epigenetic levels (119, 120) . RNA-Seq constitutes a developed deepsequencing technology approach providing an accurately measurement of the level of transcripts (30, 119). As described earlier, RNA-mediated neurodegeneration is acutely implicated in ALS. Significantly mutated RNA-binding proteins i.e. TDP43, FUS, SOD1, ubiquilin and optineurin have been found in aggregates into the motor neurons cytosol in ALS patients, leading either to their misfolding and mislocalization or to perturbed RNA metabolism. Dysregulation of RBPs has been recently emerged as a prominent pathogenic mechanism, which follows the discovery of cytoplasmic mislocalization and RBPs aggregation in afflicted sALS neurons (73, 78, 79) . RNA-Seq analysis performed by Illumina Genome Analyzer tried to interpret the effects of Fus associated with ALS pathogenesis either on wild-type or R521G and R522G mutated or knocked-down one, displaying alternatively splicing patterns (122) . DAVID Functional Annotation Tool analysis revealed significant changes in ribosomal-related genes expression in wild-type Fus overexpressed samples along with spliceosomerelated genes effectiveness upon Fus silencing. Extended data interpretation gave prominence to genes associated with RNA-binding motif regulation and endoplasmic reticulum targeting. It should be highlighted that a compelling number of differentially expressed genes has been identified increased both in R521G and R522G Fus mutant forms, demonstrating that FUS alterations may contribute to the disease mechanisms (122) .
RNA-seq methodology has been demonstrated that TDP-43 plays a significant role as an ion channel regulator, in synaptic transmission and release, in neurotransmitter 123). TDP-43 © 1996-2018 (124) . Whole transcriptome profiling study of laser capture microdissected motor neurons was performed using the transgenic G85R SOD1-YFP mouse model at a presymptomatic state, developing a compelling number of differentially expressed genes among G85R and wild-type motor neurons which are linked mainly to neuronal function (125) . More precisely, GO analysis illustrated enrichment of genes controlling neurite outgrowth, axon formation, calcium metabolism, calcium sensing, ion homeostasis and mitochondrial function. RNA-Seq analysis of motor neurons in these transgenic G85R
SOD-YFP mice identified slightly mRNA profile alterations. Post-translational effects, could involve interactions between mutant SOD1 misfolding and cellular cytosolic or membrane proteins, affecting conceivably their role in macromolecular trafficking and or synaptic organelle function (125) . RNAseq data analysis at the spinal cord of transgenic FUS R521C mice observed numerous enriched functional annotation groups which regulate extracellular matrix, including members of the collagen and cadherin gene families, phagocytosis, chemotaxis, immune-mediated processes, ion channel, synaptic specificity and neuron outgrowth (126) . The transcriptome data indicated also microglia-specific molecular markers associated either with CNS cell types or peripheral myeloid immune cells like Olfml3, Tmem119, and Siglec-H. Simultaneously, RNA-seq data demonstrated that that SOD1 G93A microglia expressed fundamental neurotoxic factors, like Mmp12, Optn, Spp1, TNF-a, IL-1b, IL-a along with receptors for type 1 Ifnar1 and Ifnar2 and the proinflammatory oxidase NOX2, evidences that attribute a complicated transcriptional profile, revealing neuroprotection and neurotoxicity concurrently (126) .
In ALS pathogenesis, it has been assumed that damaging a selective population of motor neurons leads to disease onset, duration and length of survival. It is essential to understand comprehensive disease's etiology to identify novel neuroprotective agents that might postpone either allow disorder's furtherance in parallel with the urgency of compelling therapeutic strategies able to reduce the burden of motor damage (129) (130) (131) (132) . Further research's direction should be focused on deepening our comprehension on cellular and pathological mechanisms causing ALS. The potential of transcriptomic analysis helps to define candidate genes and novel prognostic biomarkers for future investigation, disease course and treatment response. All new insights contribute to unravel transparently ALS pathogenesis demonstrating likewise perspicuous targets for future therapies. 
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